August 2025
Keep Potential Eye Risks With GLP-1 Agonists in Sight
GLP-1 agonists, such as semaglutide, have been linked to rare eye conditions - neovascular age-related macular degeneration (nAMD) and nonarteritic ischemic anterior optic neuropathy (NAION). Our article discusses the frequency of these eye conditions, their potential connection to prolonged use, and the need for further research. We provide guidance on monitoring, including baseline and annual eye exams, and emphasize the importance of reporting vision changes promptly. Finally, we offer recommendations for managing patients experiencing eye issues while on these medications. Readers can customize their own comparison of meds in this class with our new resource GLP-1 and GIP/GLP-1 Agonist Interactive Comparison Chart.
Read More:
Community Pharmacies: Put Testosterone Claims to the Test
Questions and myths about testosterone replacement therapy are common. Our article clarifies its appropriate use for men with symptoms and confirmed low testosterone levels, debunking misconceptions such as treatment for aging-related low T or the superiority of injections. Your team can use this information to educate patients on therapy options, including product differences like costs and administration, and address concerns about cardiovascular risks. Additionally, we discuss precautions to prevent topical testosterone transfer to others. For further insights, readers can stay tuned for our September 2025 Rumor vs Truth podcast where our editors will demystify other clinical claims about testosterone.
Read More:
Hospitals: Keep a Pulse on Landiolol for Arrhythmias
Your team will start to hear about landiolol (Rapiblyk), a new IV beta-blocker for atrial tachyarrhythmias such as atrial fibrillation. Our article compares landiolol to esmolol, noting its faster onset, shorter half-life, and higher beta-1 selectivity, which may reduce effects on cardiac output and blood pressure. We also address its high cost, limited indication for use under 24 hours, and similar adverse effects and contraindications to other beta-blockers. And we provide guidance on its role in therapy, dosing, and preparation. Readers can get our landiolol quick skim graphic for a snapshot of dosing, administration, side effects, and more.
Read More:
Several popular supplements have been linked to anaphylaxis. People often view supplements as safer than prescription and OTC drugs, making this a potential “hidden risk.” Our NatMed article reviews 3 popular ingredients with known anaphylaxis and allergy concerns, including Andrographis, echinacea, and soy. We advise caution, particularly in children and patients with existing allergies.
Several popular supplements have been linked to anaphylaxis. People often view supplements as safer than prescription and OTC drugs, making this a potential “hidden risk.” Our NatMed article reviews 3 popular ingredients with known anaphylaxis and allergy concerns, including Andrographis, echinacea, and soy. We advise caution, particularly in children and patients with existing allergies.
Listen to this month’s podcast episode, HIV Prevention: A Guide to PrEP and PEP, as our expert panel explores the latest pharmacologic strategies for HIV prevention—before and after exposure. You’ll listen to panelists break down key considerations for PrEP and PEP, including indications, drug selection, dosing, and monitoring.
All Medication Talk episodes offer CE credit to Pharmacist’s Letter and Prescriber Insights subscribers for 2 years after the episode release date. Go to the CE/CME & Training Organizer and search “podcast” to find available courses.
Listen to our latest episode, Zepbound for Zzz’s: Exploring Tirzepatide for Sleep Apnea, as TRC Healthcare editor, Sara Klockars, PharmD, BCPS unpacks the newly approved use of tirzepatide (Zepbound) for obstructive sleep apnea (OSA)—a first-in-class pharmacologic option for a condition long managed with devices and lifestyle changes.
Your trusted source for facts, where we dissect the evidence behind risky rumors and reveal clinical truths. This new podcast series is designed to help pharmacists, pharmacy technicians, prescribers, and even patients navigate some of the claims they might see about medication therapy. Our newest episode will be released on August 19th. In the meantime, check out our past episodes here.
Date: August 19 & 21, 2025
In this month’s live webinar, Understanding Biosimilars: From Basics to Clinical Practice, you’ll hear our panelists discuss what biosimilars are and how to incorporate them into patient care. And you’ll listen as our panelists share practical considerations for choosing and dispensing biosimilar meds.
You can submit any questions you have here and you may hear them answered during the webinar.
Available for APRNs, pharmacists, pharmacy technicians, PAs, physicians, and RNs accreditation and CE/CME:
Date: September 17, 20 & 23, 2025
In this month’s live webinar, Pet Meds Unleashed: Keeping Our Furry Patients Safe, you’ll hear our panelists discuss common therapies and unique considerations for our animal companions. And you’ll listen as our panelists share safety guidance, including how to protect pets from potentially harmful human meds.
You can submit any questions you have here and you may hear them answered during the webinar.
Available for APRNs, pharmacists, pharmacy technicians, PAs, physicians, and RNs accreditation and CE/CME:
Upcoming 2025 Live Webinars
Also, check out our upcoming Pharmacy Essential live CE webinars. Topics include:
August
*Pharmacists and pharmacy technicians can earn 1 Hour of CE for each attended webinar.
Meet us in person! Schedule a meeting with us so we can connect.
Check out where we’ll be in the coming months:
GLP-1 and GIP/GLP-1 Receptor Agonist Interactive Comparison Chart
Hypertension Goals in Adults
Our new 1-page chart summarizes blood pressure goals from various clinical guidelines for numerous clinical scenarios (cardiovascular disease, diabetes, kidney disease, etc).
Comparison of Testosterone Products
Our updated chart stacks up the advantages and disadvantages of available options by route of administration, along with dosing and cost information.
We ALWAYS Wait 30 Minutes After PEC Start-Up
By Adam West, Course and Curriculum Manager at CriticalPoint
For years, compounders have been told to wait 30 minutes to start compounding after powering up a PEC. But is that really necessary? In this month’s Compounding Chronicles blog, CriticalPoint explores the pharmacy tradition behind the “30-minute rule” and reveals how quickly ISO 5 conditions can actually be restored. Spoiler: you might be waiting for no reason.
We ALWAYS Wait 30 Minutes After PEC Start-Up
By Adam West, Course and Curriculum Manager at CriticalPoint
For years, compounders have been told to wait 30 minutes to start compounding after powering up a PEC. But is that really necessary? In this month’s Compounding Chronicles blog, CriticalPoint explores the pharmacy tradition behind the “30-minute rule” and reveals how quickly ISO 5 conditions can actually be restored. Spoiler: you might be waiting for no reason.
Behavioral health professionals are more essential than ever—and supporting them shouldn’t mean juggling multiple platforms, manual license tracking, or compliance headaches.
NetCE’s newly expanded Behavioral Health Solution makes it easy to deliver scalable, evidence-based CE and compliance training across your team. Whether you’re supporting social workers, psychologists, counselors, or psychiatric-mental health NPs, we’ve built a solution that’s as flexible and hardworking as your team.
Here's what's included:
Whether your teams are in hospitals, telehealth, clinics, or schools, we’re here to help you simplify compliance and elevate care—without adding administrative burden.
Watch this webinar for a powerful conversation with Joslyn Creighton, Pharmacy Traineeship Program Coordinator at The University of Kansas Health System, as she shared how her team built a scalable, compliant pharmacy technician training program using Pharmacy Technicians University (PTU).
TRC Healthcare Solutions Executive, Keith Marston, led the discussion with Joslyn where they covered:
Pharmacy law continues to evolve at a rapid pace—and 2025 is already shaping up to be a year of significant change. Join Sue Lunt, Director at Bula, on August 20th from 2:00-2:45pm EST, for an exclusive webinar covering the most important legislative and regulatory trends impacting pharmacy practice across the country.
In this session, Sue will walk through:
Plus, she’ll offer a brief overview of how Bula’s compliance platform tracks and simplifies pharmacy regulatory changes across all 50 states.
Whether you oversee compliance, operations, or pharmacy training, this webinar is a must-attend to stay ahead of what’s coming.
Can't make the live webinar? The session will be recorded and shared with everyone registered. Don't miss out. Register today!
*This webinar does not include CE/CME credit.